17 Amendments of Sara SKYTTEDAL related to 2021/2013(INI)
Amendment 6 #
Draft opinion
Recital A
Recital A
A. whereas the pandemic has revealed the strengths and limitations of the current set-up for managing value chains and accessibility to medicines and vaccines;
Amendment 23 #
Draft opinion
Recital B
Recital B
B. whereas universequal access toibility, affordability, and availability of medicines is a fuanda mental right the full realisation of which is incompatible with a pharmaceutical model based primarily on the pursuit of profitdicinal products is essential; whereas the EU can support this by applying a predictable policy framework that fosters public and private investments ensuring affordable patient access to medicines and benefit to society as a whole;
Amendment 26 #
Draft opinion
Recital B
Recital B
B. whereas universal access to medicines is a fundamental right the full realisation of which is incompatible with a pharmacan only be achieved through policy which inceuntical model based primarily on the pursuit of profitvises medical innovation, to the benefit of patients and society as a whole;
Amendment 47 #
Draft opinion
Recital B b (new)
Recital B b (new)
B b. whereas Europe’s pharmaceutical sector is a major contributor to the EU economy in terms of creation of highly skilled jobs and investment in innovation; whereas the pharmaceutical sector is a significant driver of trade and economic growth in the EU;
Amendment 52 #
Draft opinion
Recital B c (new)
Recital B c (new)
Amendment 73 #
Draft opinion
Paragraph 1
Paragraph 1
1. Calls on the Commission to work towards a European public biomedical infrastructure covering the entire medicines value chain and to develop the prospective European Health Emergency Response Authority (HERA) along those lines; considers that HERA should closely collaborate with public and private entities to plan, coordinate and build an ecosystem of private and public capabilities which can provide suitable emergency frameworks for EU access to key raw materials in case of global supply chocks;
Amendment 107 #
Draft opinion
Paragraph 2
Paragraph 2
2. CallPoints onut the Commission to keep the results of Union-funded R&D in the public domain; points out that the protectionat a strong EU intellectual property regime is essential for the continued innovation of medicines and vaccines, acknowledges that policy which incentivises medical innovation is in the interest of patients must not runand society at large, including by ensuring that Europe counter to the right to healthinues tobe competitive and an attractive location for R&;D investment;
Amendment 108 #
2. Calls on the Commission to keep the results of Union-funded R&D in the public domain; points out that the protection of patents must not run counter to the right to healthPoints out that the protection of the social contract between European pharmaceutical companies, patients and society as a whole rests on the EU intellectual property framework; points out that the intellectual property framework acts as a driver of investments in research and development, which is essential to innovation;
Amendment 141 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3 a. Emphasises the value of the existing intellectual property (IP) framework as the key driver of medical innovation and competitiveness; condemns any attempt to undermine the IP framework by public officials; calls on the Commission to leverage the Pharmaceutical, Industrial, Digital Strategies and the renewed EU’s trade policy to promote European competitiveness in a global market, by ensuring a sound EU IP framework that protects investment in medical research and allows industry to remain an innovator and world leader in life saving cutting edge technologies;
Amendment 172 #
Draft opinion
Paragraph 5
Paragraph 5
Amendment 190 #
Draft opinion
Paragraph 6 a (new)
Paragraph 6 a (new)
6 a. Emphasises that an increased pressure on vaccine pricing and the threat of losing IP rights could discourage investment in the development of innovative technologies, treatments and production capacity in EU thereby undermining the health of Europeans, competitiveness and jobs; stresses that vaccine prices should be reflective of the comprehensive value of vaccination to the European citizens;
Amendment 220 #
Draft opinion
Paragraph 8
Paragraph 8
Amendment 221 #
Draft opinion
Paragraph 8
Paragraph 8
Amendment 231 #
Draft opinion
Paragraph 8 a (new)
Paragraph 8 a (new)
8 a. Points out that small and medium sized enterprises (SMEs) and mid-caps play a crucial role in the pharmaceutical value chain, often as first-movers and drivers of innovation; calls on the Commission to maintain a comprehensive and predictable regulatory framework that fosters the investment and innovation of especially European pharmaceutical SMEs and mid-caps;
Amendment 244 #
Draft opinion
Paragraph 8 b (new)
Paragraph 8 b (new)
8 b. Calls on the Commission to address unjustified trade restrictions; points out that trade barriers can harm the accessibility and affordability of medicinal products;
Amendment 272 #
Draft opinion
Paragraph 8 g (new)
Paragraph 8 g (new)
8 g. Calls on the Commission and the Member States to screen foreign direct investment in pharmaceutical manufacturing plants, which are part of Europe’s critical health infrastructure;
Amendment 276 #
Draft opinion
Paragraph 8 h (new)
Paragraph 8 h (new)
8 h. Calls on the Commission to increase its involvement in supporting critical health infrastructure protection in Member States and to start applying the European Programme for Critical Infrastructure Protection to the health infrastructure sector;